Happy Hour News Briefs
Scissorhead Purplehead sends us this important message from the healthcare industry, and it kinda says it all:
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Got that? If you are cured, they cannot bleed you dry. Where’s the profit motive in that?
Yes, it is from last year, but do you really think that the ghouls in the boardroom have changed their thinking?